Public Assessment Report

Decentralised Procedure

Midazolam 5mg/ml Solution for Injection or Infusion

UK/H/1582/002/DC

UK licence no: PL 00156/0123

Martindale Pharmaceuticals Limited
LAY SUMMARY

On the 28th October 2010, the Medicine and Healthcare products Regulatory Agency (MHRA) granted Martindale Pharmaceuticals Limited a Marketing Authorisation (licence) for the medicinal product Midazolam 5mg/ml Solution for injection or infusion (PL 00156/0123). This licence was granted via the decentralised procedure (UK/H/1582/002/DC), with the UK as the Reference Member State (RMS) and Ireland as Concerned Member State (CMS).

Midazolam is one of a group of medicines known as benzodiazepines. Benzodiazepines are sedatives, meaning that they are used to relax you and help you sleep.

Midazolam Injection is used to help you feel relaxed and to help you sleep before and during an operation. It can also calm you during an operation where you are not asleep. It may also be used to help patients in intensive care units to relax.

No new or unexpected safety concerns arose from this application and it was therefore judged that the benefits of taking Midazolam 5mg/ml Solution for injection or infusion outweigh the risks; hence a Marketing Authorisation has been granted.
<table>
<thead>
<tr>
<th>Module</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Module 1: Information about initial procedure</td>
<td>4</td>
</tr>
<tr>
<td>Module 2: Summary of Product Characteristics</td>
<td>5</td>
</tr>
<tr>
<td>Module 3: Product Information Leaflets</td>
<td>18</td>
</tr>
<tr>
<td>Module 4: Labelling</td>
<td>20</td>
</tr>
<tr>
<td>Module 5: Scientific Discussion</td>
<td>23</td>
</tr>
<tr>
<td>1 Introduction</td>
<td>23</td>
</tr>
<tr>
<td>2 Quality aspects</td>
<td>26</td>
</tr>
<tr>
<td>3 Pre-clinical aspects</td>
<td>29</td>
</tr>
<tr>
<td>4 Clinical aspects</td>
<td>29</td>
</tr>
<tr>
<td>Module 6 Steps taken after initial procedure</td>
<td>32</td>
</tr>
</tbody>
</table>
## Module 1

<table>
<thead>
<tr>
<th><strong>Product Name</strong></th>
<th>Midazolam 5mg/ml Solution for injection or infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of Application</strong></td>
<td>Generic, Article 10.1</td>
</tr>
<tr>
<td><strong>Active Substance</strong></td>
<td>Midazolam hydrochloride</td>
</tr>
<tr>
<td><strong>Form</strong></td>
<td>Solution for injection or infusion</td>
</tr>
<tr>
<td><strong>Strength</strong></td>
<td>5mg/ml</td>
</tr>
</tbody>
</table>
| **Marketing Authorisation Holder** | Martindale Pharmaceuticals Ltd  
Bampton Road, Harold Hill  
Romford, Essex  
RM3 8UG, UK |
| **Reference Member State (RMS)** | UK |
| **Concerned Member State (CMS)** | Ireland |
| **Procedure Number** | UK/H/1582/002/DC |
| **End of Procedure** | 30th September 2010 |
Module 2
SUMMARY OF PRODUCT CHARACTERISTICS

The UK Summary of Product Characteristics (SmPC) for Midazolam 5mg/ml Solution for injection or infusion (PL 00156/0123) is as follows:

1 NAME OF THE MEDICINAL PRODUCT
Midazolam 5 mg/ml Solution for injection or infusion

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml of solution for injection or infusion contains 5mg midazolam (as the hydrochloride).
Each 2ml of solution for injection or infusion contains 10mg midazolam (as the hydrochloride).
Each 3ml of solution for injection or infusion contains 15mg midazolam (as the hydrochloride).
Excipient: Contains 2 mg sodium (as sodium chloride) per ml of the solution for injection or infusion

For a full list of Excipients, see section 6.1.

3 PHARMACEUTICAL FORM
Solution for injection or infusion.
Clear, colourless solution.
Ph 2.9-3.7

4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Midazolam Solution for Injection or Infusion 5 mg/ml is a short-acting sedative and sleep-inducing drug. The indications are as follows:
In adults and children
- Conscious sedation before and during diagnostic or therapeutic procedures with or without local anaesthesia,
- Premedication before induction of anaesthesia,
- Sedation in Intensive Care Units.
In adults
- Induction of anaesthesia,
- As an induction agent or as a sedative component in combined anaesthesia.

4.2 Posology and method of administration
Midazolam is a potent sedative that requires dose titration and slow administration. Dose titration is required to optimize safety whilst achieving the desired level of sedation according to the clinical need, physical status, age and concomitant medication. In adults over 60 years, debilitated or chronically ill patients and pediatric patients, the dose should be determined with caution and risk factors related to each patient should be taken into account. Standard dosages are shown in the table below; additional details are provided in the text following the table.

Standard Dosage:

<table>
<thead>
<tr>
<th>Indication</th>
<th>Adults&lt;60 years</th>
<th>Adults 60 years+/debilitated or seriously ill</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conscious sedation</td>
<td>IV Initial dose: 2-2.5mg Titrations: 1mg Total dose: 3.5-7.5mg</td>
<td>IV Initial dose: 0.5-1mg Titrations: 0.5-1mg Total dose: &lt;3.5mg</td>
<td>IV in patients 6 months-5 years Initial dose: 0.05-0.1mg/kg Total dose: &lt;6mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IV in patients 6-12 years Initial dose: 0.025-0.05mg/kg Total dose: &lt;10mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Rectal&gt;6 months 0.3-0.5mg/kg</td>
</tr>
<tr>
<td>Anaesthesia premedication</td>
<td>IM 1-15 years</td>
<td>IV initial dose; 0.5mg&lt;br&gt;Slow up titration as needed&lt;br&gt;IM 0.025-0.05mg/kg</td>
<td>Rectal&gt; 6 months</td>
</tr>
<tr>
<td>---------------------------</td>
<td>---------------</td>
<td>-------------------------------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>IM 0.07-0.1mg/kg</td>
<td>IM</td>
<td>0.05-0.15mg/kg</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Anaesthesia induction</th>
<th>IV in neonates&lt;32 weeks&lt;br&gt;gestational age&lt;br&gt;0.03 mg/kg/hr</th>
<th>IV in neonates&gt;32 weeks and children up to 6 months&lt;br&gt;0.06 mg/kg/hr</th>
<th>IV in patients&gt;6 months&lt;br&gt;0.05-0.2mg/kg&lt;br&gt;Maintenance dose: 0.06-0.12mg/kg/hr</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV 0.15-0.2mg/kg (0.3-0.35 mg/kg without premedication)</td>
<td>IV 0.1-0.2mg/kg (0.15-0.3 mg/kg without premedication)</td>
<td>IV Lower doses than recommended for adults&lt;60 years</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sedative component in combined anaesthesia</th>
<th>IV Loading dose: 0.03-0.3 mg/kg in increments of 1-2.5mg&lt;br&gt;Maintenance dose: 0.03-0.2mg/kg/hr</th>
<th>IV in neonates&lt;32 weeks&lt;br&gt;gestational age&lt;br&gt;0.03 mg/kg/hr</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>IV Intermittent doses of 0.03-0.1 mg/kg or continuous infusion of 0.03-0.1 mg/kg/hr</td>
<td>IV Lower doses than recommended for adults&lt;60 years</td>
<td>IV in neonates&gt;32 weeks and children up to 6 months&lt;br&gt;0.06 mg/kg/hr</td>
<td>IV in patients&gt;6 months&lt;br&gt;0.05-0.2mg/kg&lt;br&gt;Maintenance dose: 0.06-0.12mg/kg/hr</td>
</tr>
</tbody>
</table>

**Conscious sedation dosage**

For conscious sedation prior to diagnostic or surgical intervention, midazolam may be administered IV. The dose must be individualized and titrated, and should not be administered by rapid or single bolus injection. The onset of action is about 2 minutes after the injection. Maximum effect is obtained in about 5 to 10 minutes. However, the onset of sedation may vary individually depending on the physical status of the patient and the detailed circumstances of dosing (e.g. speed of administration, amount of dose). If necessary, subsequent doses may be administered according to the individual need.

**Adults**

The IV injection of midazolam should be given slowly at a rate of approximately 1mg in 30 seconds. In adults below the age of 60 the initial dose is 2 to 2.5 mg given 5 to 10 minutes before the beginning of the procedure. Further doses of 1mg may be given as necessary. Mean total doses have been found to range from 3.5 to 7.5 mg. A total dose greater than 5mg is usually not necessary. In adults over 60 years of age, debilitated or chronically ill patients, the initial dose is 0.5 to 1 mg. Further doses of 0.5 to 1 mg may be given as necessary. Since in these patients the peak effect may be reached less rapidly, additional midazolam should be titrated very slowly and carefully. A total dose greater than 3.5 mg is usually not necessary.

**Children**

IV administration: midazolam should be titrated slowly to the desired clinical effect. The initial dose of midazolam should be administered over 2 to 3 minutes. An additional interval of 2 to 5 minutes must be allowed to fully evaluate the sedative effect before initiating a procedure or repeating a dose. If further sedation is necessary, titration with small increments should be continued until the appropriate level of sedation is achieved. Infants and children less than 5 years of age may require substantially higher doses (mg/kg) than older children and adolescents.

- Paediatric patients less than 6 months of age are particularly vulnerable to airway obstruction and hypoventilation. For this reason, use in conscious sedation in children less than 6 months of age is not recommended.
• Paediatric patients 6 months to 5 years of age: initial dose 0.05 to 0.1 mg/kg. A total dose up to 0.6 mg/kg may be necessary to reach the desired level of sedation, but the total dose should not exceed 6mg. Prolonged sedation and risk of hypoventilation may be associated with the higher doses.
• Paediatric patients 6 to 12 years of age: initial dose 0.025 to 0.05 mg/kg. A total dose of up to 0.4mg/kg to a maximum of 10 mg may be necessary. Prolonged sedation and risk of hypoventilation may be associated with the higher doses.
• Paediatric patients 12 to 16 years of age: should be dosed as adults.

Rectal administration: the total dose of midazolam usually ranges from 0.3 to 0.5 mg/kg. Rectal administration of the ampoule solution is performed by means of a plastic applicator fixed on the end of the syringe. If the volume to be administered is too small, water may be added up to a total volume of 10ml. The total dose should be administered at once and repeated rectal administration avoided.

The use in children less than 6 months of age is not recommended, as available data in this population are limited.

IM administration: the doses used range between 0.05 and 0.15 mg/kg. A total dose greater than 10.0mg is usually not necessary. The IM route should only be used in exceptional cases. Rectal administration is preferred as IM injection is painful. In children less than 15 kg of body weight, midazolam solutions with concentrations higher than 1mg/ml are not recommended. Higher concentrations should be diluted to 1mg/ml.

ANAESTHESIA DOSAGE

Premedication
Premedication with midazolam given shortly before a procedure produces sedation (sleepiness or drowsiness and relief of apprehension) and pre-operative impairment of memory. Midazolam can also be administered in combination with anticholinergics. For this indication midazolam should be administered IM, deep into a large muscle mass 20 to 60 minutes before induction of anaesthesia, or preferably via the rectal route in children (see below). Close and continuous monitoring of the patients after administration of premedication is mandatory as inter-individual sensitivity varies and symptoms of overdose may occur.

Adults
For pre-operative sedation and to impair memory of pre-operative events, the recommended dose for adults of ASA Physical Status I & II and below 60 years is 1-2 mg i.v. repeated as needed, or 0.07 to 0.1 mg/kg administered IM. The dose must be reduced and individualised when midazolam is administered to adults over 60 years of age, debilitated, or chronically ill patients. The recommended initial i.v. dose is 0.5 mg and should be slowly uptitrated as needed. A dose of 0.025 to 0.05 mg/kg administered IM is recommended. In case of concomitant administration of narcotics the midazolam dose should be reduced. The usual dose is 2 to 3 mg.

Children over 6 months of age
Rectal administration: The total dose of midazolam, usually ranging from 0.3 to 0.5 mg/kg should be administered 15 to 30 minutes before induction of anaesthesia. Rectal administration of the ampoule solution is performed by means of a plastic applicator fixed on the end of the syringe. If the volume to be administered is too small, water may be added up to a total volume of 10 ml.

IM administration: As IM injection is painful, this route should only be used in exceptional cases. Rectal administration is preferred. However, a dose range from 0.08 to 0.2 mg/kg of midazolam administered IM has been shown to be effective and safe. In children between ages 1 and 15 years, proportionally higher doses are required than in adults in relation to body-weight. The use in children less than 6 months of age is not recommended as available data are limited. In children less than 15 kg of body weight, midazolam solutions with concentrations higher than 1 mg/ml are not recommended. Higher concentrations should be diluted to 1 mg/ml.

Induction
Adults
When midazolam is used for induction of anaesthesia before other anaesthetic agents have been administered, the individual response is variable. The dose should be titrated to the desired effect according to the patient's age and clinical status. When midazolam is used before or in combination with other IV or inhalation agents for induction of anaesthesia, the initial dose of each agent should be
significantly reduced, at times to as low as 25% of the usual initial dose of the individual agents. The desired level of anaesthesia is reached by stepwise titration. The IV induction dose of midazolam should be given slowly in increments. Each increment of not more than 5 mg should be injected over 20 to 30 seconds allowing 2 minutes between successive increments.

- In adults below the age of 60 years, an IV dose of 0.15 to 0.2 mg/kg will usually suffice. In non-premedicated adults below the age of 60 the dose may be higher (0.3 to 0.35 mg/kg IV). If needed to complete induction, increments of approximately 25% of the patient's initial dose may be used. Induction may instead be completed with inhalational anaesthetics. In resistant cases, a total dose of up to 0.6 mg/kg may be used for induction, but such larger doses may prolong recovery.
- In adults over 60 years of age, debilitated or chronically ill patients, the dose is 0.1 to 0.2 mg/kg administered IV.

Non-premedicated adults over 60 years of age usually require more midazolam for induction; an initial dose of 0.15 to 0.3 mg/kg is recommended. Non-premedicated patients with severe systemic disease or other debilitation usually require less midazolam for induction. An initial dose of 0.15 to 0.25 mg/kg will usually suffice.

Sedative component in combined anaesthesia
Adults:
Midazolam can be given as a sedative component in combined anaesthesia by either further intermittent small IV doses (range between 0.03 and 0.1 mg/kg) or continuous infusion of IV midazolam (range between 0.03 and 0.1 mg/kg/hr) typically in combination with analgesics. The dose and the intervals between doses vary according to the patient's individual reaction. In adults over 60 years of age, debilitated or chronically ill patients, lower maintenance doses will be required.

Sedation in intensive care units
The desired level of sedation is reached by stepwise titration of midazolam followed by either continuous infusion or intermittent bolus, according to the clinical need, physical status, age and concomitant medication (see section 4.5).

Adults
IV loading dose: 0.03 to 0.3 mg/kg should be given slowly in increments. Each increment of 1 to 2.5 mg should be injected over 20 to 30 seconds allowing 2 minutes between successive increments. In hypovolaemic, vasoconstricted, or hypothermic patients the loading dose should be reduced or omitted. When midazolam is given with potent analgesics, the latter should be administered first so that the sedative effects of midazolam can be safely titrated on top of any sedation caused by the analgesic.

IV maintenance dose: doses can range from 0.03 to 0.2 mg/kg/h. In hypovolaemic, vasoconstricted, or hypothermic patients the maintenance dose should be reduced. The level of sedation should be assessed regularly. With long-term sedation, tolerance may develop and the dose may have to be increased.

Children over 6 months of age
In intubated and ventilated paediatric patients, a loading dose of 0.05 to 0.2 mg/kg IV should be administered slowly over at least 2 to 3 minutes to establish the desired clinical effect. Midazolam should not be administered as a rapid intravenous dose. The loading dose is followed by a continuous IV infusion at 0.06 to 0.12 mg/kg/hr (1 to 2 μg/kg/min). The rate of infusion can be increased or decreased (generally by 25% of the initial or subsequent infusion rate) as required, or supplemental IV doses of midazolam can be administered to increase or maintain the desired effect. When initiating an infusion with midazolam in haemodynamically compromised patients, the usual loading dose should be titrated in small increments and the patient monitored for haemodynamic instability, e.g., hypotension. These patients are also vulnerable to the respiratory depressant effects of midazolam and require careful monitoring of respiratory rate and oxygen saturation.

Neonates and children up to 6 months of age
Midazolam should be given as a continuous IV infusion, starting at 0.03 mg/kg/hr (0.5 μg/kg/min) in neonates with a gestational age < 32 weeks or 0.06 mg/kg/hr (1 μg/kg/min) in neonates with a gestational age > 32 weeks and children up to 6 months. Intravenous loading doses are not recommended in premature infants, neonates and children up to 6 months, rather the infusion may be run more rapidly for the first several hours to establish therapeutic plasma levels. The rate of infusion should be carefully and frequently reassessed, particularly after the first 24 hours so as to administer
the lowest possible effective dose and reduce the potential for drug accumulation. Careful monitoring of respiratory rate and oxygen saturation is required. In premature infants, neonates and children less than 15 kg of body weight, midazolam solutions with concentrations higher than 1 mg/ml are not recommended. Higher concentrations should be diluted to 1 mg/ml.

Use in Special Populations
Renal Impairment:
In patients with renal impairment (creatinine clearance < 10 ml/min) the pharmacokinetics of unbound midazolam following a single IV dose is similar to that reported in healthy volunteers. However, after prolonged infusion in intensive care unit (ICU) patients, the mean duration of the sedative effect in the renal failure population was considerably increased most likely due to accumulation of α-hydroxymidazolam glucuronide. There is no specific data in patients with severe renal impairment (creatinine clearance below 30 ml/min) receiving midazolam for induction of anaesthesia.

Hepatic Impairment
Hepatic impairment reduces the clearance of i.v. midazolam with a subsequent increase in terminal half-life. Therefore the clinical effects may be stronger and prolonged. The required dose of midazolam may be reduced and proper monitoring of vital signs should be established. (See section 4.4).

Paediatric population
See above and see section 4.4.

4.3 Contraindications
Known hypersensitivity to benzodiazepines or to any of the ingredients in the product.
Use of midazolam for conscious sedation in patients with severe respiratory failure or acute respiratory depression.

4.4 Special warnings and precautions for use
Midazolam should be administered only by experienced physicians in a setting fully equipped for the monitoring and support of respiratory and cardiovascular function and by persons specifically trained in the recognition and management of expected adverse events including respiratory and cardiac resuscitation. Severe cardiorespiratory adverse events have occurred rarely, and include respiratory depression, apnoea, respiratory arrest and/or cardiac arrest. Such life threatening incidents are more likely to occur if the injection is given too rapidly or when a high dosage is administered. Special caution is required for the indication of conscious sedation in patients with impaired respiratory function. Paediatric patients less than 6 months of age are particularly vulnerable to airway obstruction and hypoventilation, therefore titration with small increments to clinical effect and careful monitoring of respiratory rate and oxygen saturation are essential.

When midazolam is used for premedication, adequate observation of the patient after administration is mandatory as inter-individual sensitivity varies and symptoms of overdose may occur. Special caution should be exercised when administering midazolam to high-risk patients:

- adults over 60 years of age
- chronically ill or debilitated patients, e.g.
- patients with chronic respiratory insufficiency
- patients with chronic renal failure, impaired hepatic function or with impaired cardiac function
- paediatric patients, especially those with cardiovascular instability.

These high-risk patients require lower dosages (see section 4.2) and should be continuously monitored for early signs of alterations of vital functions. Benzodiazepines should be used with caution in patients with a history of alcohol or drug abuse. As with any agent with CNS depressant and/or muscle-relaxant properties, particular care should be taken when administering midazolam to a patient with myasthenia gravis.

Tolerance
Some loss of efficacy has been reported when midazolam was used for long-term sedation in intensive care units (ICU).
Dependence
When midazolam is used for long-term sedation in ICU, it should be borne in mind that physical
dependence on midazolam may develop. The risk of dependence increases with dose and duration of
treatment; it is also greater in patients with a medical history of alcohol and/or drug abuse.

 Withdrawal symptoms
During prolonged treatment with midazolam in ICU, physical dependence may develop. Therefore,
abrupt termination of the treatment will be accompanied by withdrawal symptoms. The following
symptoms may occur: headaches, muscle pain, anxiety, tension, restlessness, confusion, irritability,
rebound insomnia, mood changes, hallucinations and convulsions. Since the risk of withdrawal
symptoms is greater after abrupt discontinuation of treatment, it is recommended to decrease doses
gradually.

Amnesia
Midazolam causes anterograde amnesia (frequently this effect is very desirable in situations such as
before and during surgical and diagnostic procedures), the duration of which is directly related to the
administered dose. Prolonged amnesia can present problems in outpatients, who are scheduled for
discharge following intervention. After receiving midazolam parenterally, patients should be
discharged from hospital or consulting room only if accompanied by an attendant.

 Paradoxical reactions
Paradoxical reactions such as agitation, involuntary movements (including tonic/clonic convulsions
and muscle tremor), hyperactivity, hostility, rage reaction, aggressiveness, paroxysmal excitement and
assault, have been reported to occur with midazolam. These reactions may occur with high doses
and/or when the injection is given rapidly. The highest incidence to such reactions has been reported
among children and the elderly.

Altered elimination of midazolam
Midazolam elimination may be altered in patients receiving compounds that inhibit or induce the
isoenzyme CYP3A4 and the dose of midazolam may need to be adjusted accordingly (see section 4.5).
Midazolam elimination may also be delayed in patients with liver dysfunction, low cardiac output and
in neonates (see section 5.2).

Preterm infants and neonates
Due to an increased risk of apnoea, extreme caution is advised when sedating pre-term and former pre-
term patients. Careful monitoring of respiratory rate and oxygen saturation is required. Rapid injection
should be avoided in neonates. Neonates have reduced and/or immature organ function and are also
vulnerable to profound and/or prolonged respiratory effects of midazolam. Adverse haemodynamic
events have been reported in paediatric patients with cardiovascular instability; rapid intravenous
administration should be avoided in this population.

Paediatric patients less than 6 months:
In this population, midazolam is indicated for sedation in ICU only. Paediatric patients less than 6
months of age are particularly vulnerable to airway obstruction and hypoventilation, therefore titration
with small increments to clinical effect and careful respiratory rate and oxygen saturation monitoring
are essential (see also section ‘Preterm infants’ above).

Concomitant use of alcohol / CNS depressants:
The concomitant use of midazolam with alcohol or and CNS depressants should be avoided. Such
concomitant use has the potential to increase the clinical effects of midazolam possibly including
severe sedation or clinically relevant respiratory depression (see section 4.5).

Medical history of alcohol or drug abuse:
Midazolam as other benzodiazepines should be avoided in patients with a medical history of alcohol or
drug abuse.

Discharging criteria
After receiving midazolam, patients should be discharged from hospital or consulting room only when
recommended by treating physician and if accompanied by an attendant. It is recommended that the
patient is accompanied when returning home after discharge.
4.5 Interaction with other medicinal products and other forms of interaction

Pharmacokinetic interactions

Midazolam is metabolised by CYP3A4.
Inhibitors and inducers of CYP3A4 have the potential to respectively increase and decrease the plasma concentrations and, subsequently, the effects of midazolam thus requiring dose adjustments accordingly.

Pharmacokinetic interactions with CYP3A4 inhibitors or inducers are more pronounced for oral as compared to i.v. midazolam, in particular since CYP3A4 also exists in the upper gastro-intestinal tract. This is because for the oral route both systemic clearance and availability will be altered while for the parenteral route only the change in the systemic clearance becomes effective.

After a single dose of IV midazolam, the consequence on the maximal clinical effect due to CYP3A4 inhibition will be minor while the duration of effect may be prolonged. However, after prolonged dosing of midazolam, both the magnitude and duration of effect will be increased in the presence of CYP3A4 inhibition.

There are no available studies on CYP3A4 modulation on the pharmacokinetics of midazolam after rectal and intramuscular administration. It is expected that these interactions will be less pronounced for the rectal than for the oral route because the gastro-intestinal tract is by-passed whereas after IM administration the effects of CYP3A4 modulation should not substantially differ from those seen with IV midazolam.

It is therefore recommended to carefully monitor the clinical effects and vital signs during the use of midazolam, taking into account that they may be stronger and last longer after co-administration of a CYP3A4 inhibitor, be it given only once. Notably, administration of high doses or long-term infusions of midazolam to patients receiving strong CYP3A4 inhibitors, e.g. during intensive care, may result in long-lasting hypnotic effects, delayed recovery and respiratory depression thus requiring dose adjustments.

With respect to induction, it should be considered that the inducing process needs several days to reach its maximum effect and also several days to dissipate. Contrary to a treatment of several days with an inducer, a short-term treatment is expected to result in less apparent DDI with midazolam. However, for strong inducers a relevant induction even after short-term treatment cannot be excluded.

Midazolam is not known to change the pharmacokinetics of other drugs.

Drugs that inhibit CYP3A4:

Azole antifungals:

- Ketoconazole increased the plasma concentrations of intravenous midazolam by 5-fold while the terminal half-life increased by about 3-fold. If parenteral midazolam is co-administered with the strong CYP3A4 inhibitor ketoconazole, it should be done in an intensive care unit (ICU) or similar setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Staggered dosing and dosage adjustment should be considered, especially if more than a single i.v. dose of midazolam is administered. The same recommendation may apply also for other azole antifungals (see further), since increased sedative effects of IV midazolam, although lesser, are reported.

- Voriconazole increased the exposure of intravenous midazolam by 3-fold whereas its elimination half-life increased by about 3-fold.

- Fluconazole and itraconazole both increased the plasma concentrations of intravenous midazolam by 2–3-fold associated with an increase in terminal half-life by 2.4-fold for itraconazole and 1.5-fold for fluconazole, respectively.

- Posaconazole increased the plasma concentrations of intravenous midazolam by about 2-fold.

- It should be kept in mind that if midazolam is given orally, its exposure will drastically be higher than the abovementioned ones, notably with ketoconazole, itraconazole, voriconazole.

Midazolam ampoules are not indicated for oral administration.

Macrolide antibiotics
• Erythromycin resulted in an increase in the plasma concentrations of intravenous midazolam by about 1.6 – 2-fold associated with an increase of the terminal half-life of midazolam by 1.5 – 1.8-fold.

Clarithromycin increased the plasma concentrations of midazolam by up to 2.5-fold associated with an increase in terminal half-life by 1.5 – 2-fold.

Additional information from oral midazolam

• Roxithromycin: While no information on roxithromycin with IV midazolam is available, the mild effect on the terminal half-life of oral midazolam tablet, increasing by 30%, indicates that the effects of roxithromycin on intravenous midazolam may be minor.

HIV Protease inhibitors

• Saquinavir and other HIV protease inhibitors: Co-administration with protease inhibitors may cause a large increase in the concentration of midazolam. Upon co-administration with ritonavir-boosted lopinavir, the plasma concentrations of intravenous midazolam increased by 5.4-fold, associated with a similar increase in terminal half-life. If parenteral midazolam is coadministered with HIV protease inhibitors, treatment setting should follow the description in the above section for azole antifungals, ketoconazole.

Additional information from oral midazolam
Based on data for other CYP3A4 inhibitors, plasma concentrations of midazolam are expected to be significantly higher when midazolam is given orally. Therefore protease inhibitors should not be co-administered with orally administered midazolam.

Calcium-channel blockers

• Diltiazem: A single dose of diltiazem increased the plasma concentrations of intravenous midazolam by about 25% and the terminal half-life was prolonged by 43%.

Additional information from oral midazolam

• Verapamil / diltiazem increased the plasma concentrations of oral midazolam by 3- and 4-fold, respectively. The terminal half-life of midazolam was increased by 41% and 49% respectively.

Various drugs/Herbs

• Atorvastatin showed a 1.4-fold increase in plasma concentrations of IV midazolam compared to control group.

Additional information from oral midazolam

• Nefazodone increased the plasma concentrations of oral midazolam by 4.6-fold with an increase of its terminal half-life by 1.6-fold.

• Aprepitant dose-dependently increased the plasma concentrations of oral midazolam by 3.3-fold after 80 mg/day associated with an increase in terminal half-life by ca. 2-fold.

Drugs that induce CYP3A4

• Rifampicin decreased the plasma concentrations of intravenous midazolam by about 60% after 7 days of rifampicin 600 mg o.d. The terminal half-life decreased by about 50-60%.

Additional information from oral midazolam

• Rifampicin decreased the plasma concentrations of oral midazolam by 96% in healthy subjects and its psychomotor effects were almost totally lost.

Carbamazepine/ phenytoin: Repeated dosages of carbamezepine or phenytoin resulted in a decrease in plasma concentrations of oral midazolam by up to 90% and a shortening of the terminal half-life by about 60%.

Efavirenz: The 5-fold increase in the ratio of the CYP3A4 generated metabolite α-hydroxymidazolam to midazolam confirms its CYP3A4-inducing effect.
Herbs and food
• St John’s Wort decreased plasma concentrations of midazolam by about 20 - 40% associated with a decrease in terminal half-life of about 15 - 17%. Depending on the specific St John’s Wort extract, the CYP3A4-inducing effect may vary.

Pharmacodynamic:

Drug-Drug Interactions (DDI):
The co-administration of midazolam with other sedative/hypnotic agents and CNS depressants, including alcohol, is likely to result in enhanced sedation and respiratory depression. Examples include opiate derivatives (be they used as analgesics, antitussives or substitutative treatments), antipsychotics, other benzodiazepines used as anxiolytics or hypnotics, barbiturates, propofol, ketamine, etomidate; sedative antidepressants, non recent HI-antihistamines and centrally acting antihypertensive drugs.
Alcohol may markedly enhance the sedative effect of midazolam. Alcohol intake should be strongly avoided in case of midazolam administration (see section 4.4).
Midazolam decreases the minimum alveolar concentration (MAC) of inhalational anaesthetics.

4.6 Pregnancy and lactation

There are insufficient data available on midazolam to assess its safety during pregnancy. Animal studies do not indicate a teratogenic effect, but foetotoxicity was observed as with other benzodiazepines. No data on exposed pregnancies are available for the first two trimesters of pregnancy. The administration of high doses of midazolam in the last trimester of pregnancy, during labour or when used as an induction agent of anaesthesia for caesarean section has been reported to produce maternal or foetal adverse effects (inhalation risk in mother, irregularities in the foetal heart rate, hypotonia, poor sucking, hypothermia and respiratory depression in the neonate). Moreover, infants born from mothers who received benzodiazepines chronically during the latter stage of pregnancy may have developed physical dependence and may be at some risk of developing withdrawal symptoms in the postnatal period. Consequently, midazolam should not be used during pregnancy unless clearly necessary. It is preferable to avoid using it for caesarean section. The risk for the neonate should be taken into account in case of administration of midazolam for any surgery near the term.

Midazolam passes in low quantities into breast milk. Nursing mothers should be advised to discontinue breast-feeding for 24 hours following administration of midazolam.

4.7 Effects on ability to drive and use machines

Sedation, amnesia, impaired attention and impaired muscular function may adversely affect the ability to drive or use machines. Prior to receiving midazolam, the patient should be warned not to drive a vehicle or operate a machine until completely recovered. The physician should decide when these activities may be resumed. It is recommended that the patient is accompanied when returning home after discharge.

4.8 Undesirable effects

The following frequencies have been used:
Very common (≥ 1/10)
Common (≥ 1/100 to < 1/10)
Uncommon (≥ 1/1,000 to <1/100)
Rare (≥ 1/10,000 to <1/1,000)
Very rare (<1/10,000)
Not known (cannot be estimated from the available data).

The following undesirable effects have been reported (very rarely) to occur when midazolam is injected:
Immune System Disorders: Generalised hypersensitivity reactions (skin reactions, cardiovascular reactions, bronchospasm), anaphylactic shock.
Psychiatric Disorders: Confusional state, euphoric mood, hallucinations.
Paradoxical reactions such as agitation, involuntary movements (including tonic/clonic movements and muscle tremor), hyperactivity, hostility, rage reaction, aggressiveness, paroxysmal excitement and assault, have been reported, particularly among children and the elderly.
Dependence: Use of midazolam - even in therapeutic doses - may lead to the development of physical dependence. After prolonged i.v. administration, discontinuation, especially abrupt discontinuation of the product, may be accompanied by withdrawal symptoms including withdrawal convulsions (see section 4.4).

Nervous System Disorders: Prolonged sedation, decreased alertness, somnolence, headache, dizziness, ataxia, postoperative sedation, anterograde amnesia, the duration of which is directly related to the administered dose. Anterograde amnesia may still be present at the end of the procedure and in isolated cases prolonged amnesia has been reported.

Convulsions have been reported in premature infants and neonates.

Cardiac Disorders: Severe cardiorespiratory adverse events have occurred. These have included cardiac arrest, hypotension, bradycardia, vasodilating effects. Life-threatening incidents are more likely to occur in adults over 60 years of age and those with pre-existing respiratory insufficiency or impaired cardiac function, particularly when the injection is given too rapidly or when a high dosage is administered (see section 4.4).

Respiratory Disorders: Severe cardiorespiratory adverse events including respiratory depression, apnoea, respiratory arrest, dyspnoea, laryngospasm have been reported. Life-threatening incidents are more likely to occur in adults over 60 years of age and those with pre-existing respiratory insufficiency or impaired cardiac function, particularly when the injection is given too rapidly or when a high dosage is administered (see section 4.4). Hiccup.

Gastrointestinal System Disorders: Nausea, vomiting, constipation, dry mouth.

Skin and Appendages Disorders: Skin rash urticaria, pruritus.

General and Application Site Disorders: Fatigue, erythema and pain on injection site, thrombophlebitis, thrombosis.

Injury, Poisoning and Procedural Complications: An increased risk for falls and fractures has been recorded in elderly benzodiazepine users.

4.9 Overdose

Symptoms
The symptoms of overdose are mainly an intensification of the pharmacological effects; drowsiness, mental confusion, lethargy and muscle relaxation or paradoxical excitation. More serious symptoms would be areflexia, hypotension, cardiorespiratory depression, apnoea and coma. Coma, if it occurs, usually lasts a few hours but it may be more protracted and cyclical, particularly in elderly patients. Benzodiazepine respiratory depressant effects are more serious in patients with respiratory disease. Benzodiazepines increase the effects of other central nervous system depressants, including alcohol.

Treatment
Monitor the patient’s vital signs and institute supportive measures as indicated by the patient’s clinical state. In particular, patients may require symptomatic treatment for cardiorespiratory effects or central nervous system effects.

If taken orally further absorption should be prevented using an appropriate method e.g. treatment within 1-2 hours with activated charcoal. If activated charcoal is used airway protection is imperative for drowsy patients. In case of mixed ingestion gastric lavage may be considered, however not as a routine measure.

If CNS depression is severe consider the use of flumazenil, a benzodiazepine antagonist. This should only be administered under closely monitored conditions. It has a short half-life (about an hour), therefore patients administered flumazenil will require monitoring after its effects have worn off. Flumazenil is to be used with extreme caution in the presence of drugs that reduce seizure threshold (e.g. tricyclic antidepressants). Refer to the prescribing information for flumazenil, for further information on the correct use of this drug.
5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Hypnotics and sedatives, benzodiazepine derivatives, ATC code: N05CD08

Midazolam is a derivative of the imidazobenzodiazepine group. It has pronounced sedative and sleep-inducing effects and it also exerts anxiolytic, anticonvulsant and muscle-relaxing effects. The pharmacological action of midazolam is of short duration because of rapid metabolic transformation. Midazolam forms water-soluble salts with acids, producing a stable and well-tolerated injection solution. Following IV or IM administration of midazolam, anterograde amnesia occurs and the patient does not remember events that took place during the maximal activity of midazolam.

5.2 Pharmacokinetic properties

Absorption after IM injection
Absorption of midazolam from muscle is rapid and complete. Maximum plasma concentrations are reached within 30 minutes. The absolute bioavailability after IM injection is over 90%.

Absorption after rectal administration
After rectal administration midazolam is absorbed rapidly. Maximum plasma concentration is reached in about 30 minutes. The absolute bioavailability is about 50%.

Distribution
Following IV injection of midazolam, the plasma concentration-time curve shows one or two distinct phases of distribution. The volume of distribution at steady state is 0.7 - 1.2 l/kg. Midazolam is extensively bound (96-98%) to plasma proteins, mainly to albumin. There is a slow and insignificant passage of midazolam into the cerebrospinal fluid. In humans, midazolam has been shown to cross the placenta slowly and to enter the foetal circulation. Small quantities of midazolam are found in human milk.

Metabolism
Midazolam is almost entirely eliminated by biotransformation. The fraction of the dose extracted by the liver has been estimated to be 30 - 60%. Midazolam is hydroxylated by the cytochrome P4503A4 isoenzyme and the major urinary and plasma metabolite is alpha-hydroxymidazolam. Plasma concentrations of alpha-hydroxymidazolam are 12% of those of the parent compound. Although pharmacologically active, this metabolite contributes only minimally (about 10%) to the effects of intravenous midazolam.

Elimination
In healthy volunteers, the elimination half-life of midazolam is between 1.5 - 2.5 hours. Plasma clearance is in the range of 300 – 500 ml/min. Midazolam is excreted mainly by the kidneys (60 - 80% of the injected dose) and recovered as glucuroconjugated alpha-hydroxymidazolam; less than 1% of the dose is recovered in urine as unchanged drug. The elimination half-life of alpha-hydroxymidazolam is less than 1 hour. When midazolam is given by IV infusion, its elimination kinetics does not differ from those following bolus injection.

Pharmacokinetics in special populations
Elderly
In adults over 60 years of age, the elimination half-life may be prolonged up to four times.

Children
The rate of rectal absorption in children is similar to that in adults but the bioavailability is 5-18% lower. The elimination half-life after IV and rectal administration is shorter in children 3 - 10 years old (1 - 1.5 hours) as compared with that in adults, the difference being consistent with an increased metabolic clearance in children.

Neonates
In neonates the elimination half-life is on average 6 - 12 hours, probably due to liver immaturity and the clearance is reduced (see 4.4 Special warnings and precautions for use).
Obese
The mean half-life is longer in obese than in non-obese patients (5.9 vs 2.3 hours), due to an increase of approximately 50% in the volume of distribution corrected for total body weight. The clearance is not significantly different in obese and non-obese patients.

Patients with hepatic impairment
The elimination half-life in cirrhotic patients may be longer and the clearance smaller as compared to those in healthy volunteers (see 4.4 Special warnings and precautions for use).

Patients with renal impairment
The elimination half-life in patients with chronic renal failure is similar to that in healthy volunteers.

Critically ill patients
The elimination half-life of midazolam is prolonged up to six times in critically ill patients.

Patients with cardiac insufficiency
The elimination half-life is longer in patients with congestive heart failure compared with that in healthy subjects (see 4.4 Special warnings and precautions for use).

5.3 Preclinical safety data
There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Sodium Chloride
Dilute Hydrochloric Acid
Sodium Hydroxide (for pH adjustment)
Water for Injections

6.2 Incompatibilities
Admixture with Hartmann’s solution is not recommended, as the potency of midazolam decreases.
This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6

6.3 Shelf life
Unopened: 2 years
Diluted: 24 hours
Chemical and physical in-use stability has been demonstrated for 24 hours at 2-8°C, from a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution/dilution has taken place in controlled and validated conditions.

6.4 Special precautions for storage
This medicinal product does not require any special temperature storage conditions. Keep the ampoules in the outer carton in order to protect from light.
For the storage condition of the diluted medicinal product see section 6.3

6.5 Nature and contents of container
Clear type I glass ampoules.
2 ml and 5 ml type I glass ampoules in packs of 10.
Not all pack sizes may be marketed.

6.6 Special precautions for disposal
For single use only.
Any unused product or waste material should be disposed of in accordance with local requirements.
The product should be used immediately after opening.
Diluted product should be discarded if not used within 24 hours. (See section 6.3)
Do not use the product if the solution is discolored (see section 3).
The solution for injection or infusion should be examined visually before administration. Only solutions without visible particles should be used.

Compatible solutions for infusions are as follows:

i) 5% Glucose Intravenous Infusion BP
ii) Sodium Chloride Intravenous Infusion BP
iii) 0.18% Sodium Chloride and 4% Glucose Intravenous Infusion BP

For continuous intravenous infusion, Midazolam solution for injection may be diluted to the range of 0.05mg-1mg/ml with infusion solutions listed above.

7 MARKETING AUTHORISATION HOLDER
Martindale Pharmaceuticals
Bampton Road,
Romford,
Essex
RM3 8UG

8 MARKETING AUTHORISATION NUMBER(S)
PL 00156/0123

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
28/10/2010

10 DATE OF REVISION OF THE TEXT
28/10/2010
Module 3
Product Information Leaflet

PAR Midazolam 5mg/ml Solution for injection or infusion

Midazolam Hydrochloride

Read all of this leaflet carefully before you start using this medicine.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:
1. What Midazolam is and what it is used for
2. Before Midazolam is given
3. How Midazolam will be given
4. Possible side effects
5. How to store Midazolam solution for Injection or Infusion
6. Further information

1. What Midazolam is and what it is used for

Midazolam is one of a group of medicines known as benzodiazepines. Benzodiazepines are sedatives, meaning that they are used to relax you and help you to sleep.

Midazolam Injection is used to help you feel relaxed and to help you sleep before and during an operation. It can also calm you during an operation where you are not asleep. It may also be used to help patients in intensive care units to relax.

2. Before Midazolam is given

You should not be given Midazolam:
- If you are allergic or hypersensitive to Midazolam or any of the ingredients in the product.
- If you have severe breathing difficulties or problems with your lungs.

Take special care with Midazolam if:
- You have severe or moderate breathing difficulties.
- You are over 60 years of age.
- It is to be given to children, especially those suffering heart or blood vessel problems (cardiovascular).
- You have severe kidney problems.
- You have problems with your heart or have a heart condition.
- You have a history of alcohol or drug abuse or have liver disease.
- You have a condition called ‘myasthenia gravis’.
- You are debilitated (have an illness that makes you feel very weak, run down and short of energy).
- You are pregnant or think you may be pregnant (see ‘Pregnancy and breast-feeding’).

If any of the above applies to you, please tell your doctor.

Taking other medicines:
Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. This includes:
- Antifungal medicines such as itraconazole, fluconazole, voriconazole, ketoconazole or posaconazole.
- Medicines to reduce blood pressure such as warfarin or diuretics.
- Medicines to treat high cholesterol such as atorvastatin.
- Medicines to treat mycobacterial infections such as rifampicin.
- Antibiotics prescribed by your doctor such as erythromycin or clindamycin.
- HIV medications such as saquinavir, ritonavir, indinavir, nevirapine and amphotericin.
- Drugs that depress the central nervous system (cause drowsiness) such as phenytoin or carbamazepine.
- Alcohol or drugs containing alcohol.
- General anaesthetics (given by inhalation).
- Strong painkillers.
- The herbal medicine St. John’s Wort.

If you are in any doubt please tell your doctor about any medication you are taking.

Pregnancy and breast-feeding:
This medicine should not be used during pregnancy unless your doctor feels it is necessary.

Midazolam passes in low amounts into breast milk. Nursing mothers are advised to stop breast-feeding for 24 hours following administration of midazolam.

Please speak to your doctor if you are pregnant, trying to become pregnant or are breast-feeding.

Driving and using machinery:
This medicine may adversely affect your ability to drive or use machines. You should not drive a vehicle or operate a machine until completely recovered. Your physician should decide when these activities may be resumed. It is recommended that you are accompanied when returning home after you are discharged from hospital.

Important information about some of the ingredients of Midazolam:
Midazolam Injection is essentially ‘sodium free’ as it contains less than 1mmol sodium (23mg) per ampoule.

3. How Midazolam is given

Adults and the elderly:
Midazolam Injection will be given to you by a doctor or nurse slowly in a vein (intravenous) either as a continuous infusion or intermittent bolus injection into a muscle. Your doctor will decide the correct dosage for you as this would be dependent on your general physical condition, age, weight and your response to treatment and whether other medicines are needed at the same time.

Children:
The precise dose and route of administration must be decided by a doctor qualified in the treatment of children.

Continued overleaf
If you are given too much Midazolam:
As this medicine will be given to you whilst you are in hospital it is unlikely that you will be given too little or too much, however, tell your doctor, nurse or pharmacist if you have any concerns.

If you stop taking Midazolam
During prolonged treatment with Midazolam, physical dependence may develop. Suddenly stopping the treatment may be accompanied by withdrawal symptoms. The following symptoms may occur: headaches, muscle pain, anxiety, tension, restlessness, confusion, irritability, rebound insomnia (unable to sleep), mood changes, hallucinations and convulsions. Since the risk of withdrawal symptoms is greater after suddenly stopping treatment, it is recommended to stop doses gradually.
If you have any further questions on the use of this product, ask your doctor or pharmacist.

4. Possible side effects
Like all medicines Midazolam can cause side effects, although not everybody gets them.
If any of the following symptoms occur contact your doctor or nearest accident and emergency department immediately. These are symptoms of a serious allergic reaction:
- skin irritation or rash including redness, itchiness and swelling
Other side effects:
- drowsiness
- prolonged sedation (sleepiness)
- reduced alertness or confusion
- euphoria (state of excitement)
- hallucinations
- fatigue
- headache
- diziness
- ataxia (reduced control of limb movements)
- amnesia (memory loss)
- agitation
- hyperactivity
- hervility
- rage
- aggressiveness
- convulsions (muscle tightening and relaxing)
- nausea
- vomiting
- hiccup
- coughing
- constipation
- dry mouth
- chest pain or problems with your heart
- heart failure
- changes in heart rate
- breathing difficulties, such as spasms of the airway tract
- stopping breathing
- Swelling or pain on injection site
- Blood clots at the site of injection
- Addiction
- Low blood pressure
- Rash and itching
- Muscle tremor
If any of the side effects get serious, or you notice any side effects not listed in the leaflet, please tell your doctor or pharmacist.

5. How to store Midazolam
Your doctor or pharmacist is responsible for storing Midazolam injection. They are also responsible for disposing of any unused Midazolam. You should not be given Midazolam injection after the expiry date which is stated on the carton and ampoule. The expiry date refers to the last date of the month.
Keep out of the reach and sight of children.
This medicinal product does not require any special temperature storage conditions.
Keep the container in the outer carton in order to protect from light.
Your doctor or nurse should not use this product if the solution is discoloured.

6. Further Information
What Midazolam contains
The active ingredient is Midazolam (as hydrochloride). Each 2ml of solution for injection or infusion contains 10mg midazolam (as the hydrochloride). Each 3ml of solution for injection or infusion contains 15mg midazolam (as the hydrochloride).
The other ingredients are water for injections, dilute hydrochloric acid, sodium chloride and sodium hydroxide.
Each ml of solution for injection contains 5mg of Midazolam (as the hydrochloride).

What Midazolam looks like and contents of the pack:
Midazolam solution for injection is a clear colourless solution, filled in clear glass ampoules.
The medicine is supplied to your pharmacist or doctor in packs of 10 clear glass ampoules (2ml and 3ml).

Marketing Authorisation Holder and Manufacturer:
Martindale Pharmaceuticals,
Bampton Road,
Harold Hill,
Romford,
RM3 8UG,
United Kingdom.

Product Licence Number (s):
PL 00156/0123 PA 391/21/1

For any information about this medicine, please contact the Marketing Authorisation Holder details provided above.
This leaflet was approved in: 10/2010

Martindale Pharma
Bampton Road, Harold Hill, Romford, RM3 8UG, UK
Module 4
Labelling

Carton

15mg in 3ml
Martindale Pharmaceuticals
Midazolam 5mg/ml
Solution for injection and infusion
5mg in 1ml, 15mg in 3ml.
For IV, IM and rectal use.
Fatal if given by other routes.
Read the package leaflet before use.
PLU01560123 PA 35/231/1
Lot:
Exp:

10mg in 2ml
Martindale Pharmaceuticals
Midazolam 5mg/ml
Solution for injection and infusion
5mg in 1ml, 10mg in 2ml.
For IV, IM and rectal use.
Fatal if given by other routes.
Read the package leaflet before use.
PLU01560123 PA 35/231/1
Lot:
Exp:
Midazolam 5mg/ml Solution for Injection or Infusion

For Intravenous, Intramuscular and rectal use

Solution for Injection or Infusion

Each ml of solution for Injection or Infusion contains:

5mg midazolam as the hydrochloride. One ampoule of 2ml contains 10mg midazolam as midazolam hydrochloride. Sodium Chloride, Sodium Chloride for injection,

Accord Healthcare Limited Accord HealthCare Limited

Keep the ampoules in the outer carton in order to protect from light. Store the enclosed labels before use

Revised: 2006/01/26 K-A3209/1

Meadowside Pharmaceuticals, Reowdred, Essex RM2 5UG. UK.
Module 5
Scientific discussion during initial procedure

I  INTRODUCTION
On 30th September Ireland and the UK agreed to grant a Marketing Authorisation (MA) to Martindale Pharmaceuticals Limited for the medicinal product Midazolam 5mg/ml Solution for injection or infusion. The MA was granted via a Decentralised Procedure (DCP), with the UK as Reference Member State (RMS UK/H/1582/002/DC). After the national phase, an MA was granted in the UK on 28th October 2010 (PL 00156/0123).

This application was made under Article 10.1 of Directive 2001/83/EC for Midazolam 5mg/ml Solution for injection or infusion, containing the known active substance midazolam hydrochloride. The reference medicinal product for this application is Hypnovel ampoules 10mg/2ml (PL 00031/0126) first licensed on 8th December 1982 to Roche Products Ltd.

Midazolam is a drug which is a benzodiazepine derivate (ATC code: N05CD08). It has powerful anxiolytic, anaesthetic, hypnotic, anticonvulsant, skeletal muscle relaxant and sedative properties. It is considered a short-acting benzodiazepine, with a short elimination half-life. As such it binds to benzodiazepine receptors in various regions of the CNS such as the spinal cord, brain stem, cerebellum, limbic system and the cerebral cortex. It is mainly used for sedation in surgical or investigational procedures.

No new preclinical or clinical efficacy studies were conducted for this application, which is acceptable given that the application was for a generic version of product that has been licensed for over 10 years. A bioequivalence study is not necessary to support this application for a parenteral product.

The RMS has been assured that acceptable standards of Good Manufacturing Practice (GMP) are in place for these product types at all sites responsible for the manufacture and assembly of these products. Evidence of compliance with GMP has been provided for the named manufacturing and assembly sites. For manufacturing sites within the Community, the RMS has accepted copies of current manufacturer authorisations issued by inspection services of the competent authorities as certification that acceptable standards of GMP are in place at those sites.

For manufacturing sites outside the community, the RMS has accepted copies of current GMP certificates or satisfactory inspection summary reports, ‘close-out letters’ or ‘exchange of information’ issued by the inspection services of the competent authorities (or those countries with which the EEA has a Mutual Recognition Agreement for their own territories) as certification that acceptable standards of GMP are in place at those non-Community sites.

The RMS considers that the pharmacovigilance system, as described by the MAH, fulfils the requirements and provides adequate evidence that the MAH has the services of a qualified person responsible for pharmacovigilance and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country. The Marketing Authorisation Holder has provided adequate justification for not submitting a Risk Management Plan (RMP). As the application is for a generic version of an already authorised reference product, for which safety concerns requiring additional risk minimisation have not been identified, a risk minimisation system is not considered necessary. The reference product has been in use for many years and the safety profile of the active is well established.
The Marketing Authorisation Holder has provided adequate justification for not submitting an Environmental Risk Assessment (ERA). This was an application for a generic product and there is no reason to conclude that marketing of this product will change the overall use pattern of the existing market.
## II. ABOUT THE PRODUCT

<table>
<thead>
<tr>
<th>Name of the product in the Reference Member State</th>
<th>Midazolam 5mg/ml Solution for injection or infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name(s) of the active substance(s) (INN)</td>
<td>Midazolam hydrochloride</td>
</tr>
<tr>
<td>Pharmacotherapeutic classification (ATC code)</td>
<td>N05CD 08</td>
</tr>
<tr>
<td>Pharmaceutical form and strength(s)</td>
<td>Solution for injection or infusion 5 mg/ml</td>
</tr>
<tr>
<td>Reference numbers for the Decentralised Procedure</td>
<td>UK/H/1582/02/DC</td>
</tr>
<tr>
<td>Reference Member State</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Member States concerned</td>
<td>Ireland</td>
</tr>
<tr>
<td>Marketing Authorisation Number(s)</td>
<td>PL 00156/0123</td>
</tr>
</tbody>
</table>
| Name and address of the authorisation holder     | Martindale Pharmaceuticals Ltd
                                                  | Bampton Road, Harold Hill
                                                  | Romford, Essex
                                                  | RM3 8UG, UK                                    |
III  SCIENTIFIC OVERVIEW AND DISCUSSION

III.1  QUALITY ASPECTS

DRUG SUBSTANCE

INN  Midazolam hydrochloride

Chemical name: 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1, 5-a][1, 4]benzodiazepine

Structure:

![Structure](image)

Molecular formula: C\textsubscript{18}H\textsubscript{13}ClFN\textsubscript{3}

Molecular weight: 325.8

General Properties

Description: White or yellowish, crystalline powder

Solubility: Practically insoluble in water, freely soluble in acetone and in ethanol (96%), soluble in methanol.

The active substance, midazolam hydrochloride is the subject of a European Pharmacopeia (Ph. Eur.) monograph.

Manufacture

All aspects of the manufacture and control of the active substance midazolam hydrochloride are covered by a European Directorate for the Quality of Medicines (EDQM) Certificate of Suitability.

The active substance is stored in appropriate packaging. Specifications and Certificates of Analysis have been provided for the packaging materials used. The primary packaging material in direct contact with the active substance satisfy Directive 2002/72/EC (as amended), and are suitable for contact with foodstuffs.

Appropriate stability data have been presented for the active substance stored in packaging representative of the proposed commercial packaging. These data demonstrate the stability of the active substance. A suitable re-test period has been applied when stored in the stated container closure system.

DRUG PRODUCT

Description and Composition

Midazolam 5mg/ml Solution for injection or infusion is presented as a clear, colourless solution containing 5mg of the active ingredient midazolam, as midazolam hydrochloride.

Other Ingredients

Other ingredients consist of pharmaceutical excipients, namely sodium chloride, dilute hydrochloride acid, sodium hydroxide (pH adjustments) and water for injections. All excipients used comply with their relevant Ph.Eur monographs. Satisfactory Certificates of
Analysis have been provided for all excipients. The applicant has provided a declaration confirming that there are no materials of human or animal origin contained in, or used in the manufacturing process for the proposed product. Furthermore, no genetically modified organisms are used in the manufacture of the finished product.

**Pharmaceutical Development**

The aim of the pharmaceutical development programme was to produce a generic equivalent of the reference product Hypnovel 10mg/2ml solution for injection. Suitable pharmaceutical development data have been provided for this application.

The physico-chemical properties of the drug product have been compared with the reference product. These data demonstrate that the proposed product can be considered a generic medicinal product of Hypnovel 10mg/2ml solution for injection (PL 00031/0126) licensed to Roche Products Limited.

**Impurities**

The impurities in the finished product are the same as those stated in the Ph.Eur monograph of the active substance, midazolam hydrochloride. The impurities are controlled to limits stated in the Ph.Eur monograph and Certificate of Suitability.

Comparative analyses have been presented for the applicants’ product and the reference product and the results are similar.

**Manufacture**

A description and flow-chart of the manufacturing method has been provided.

In-process controls were considered appropriate considering the nature of the product and the method of manufacture. Process validation studies have been conducted and are accepted. Satisfactory analytical results from three commercial-scale batches have been provided.

**Finished Product Specification**

Finished product specifications are provided for both release and shelf-life, and are satisfactory; they provide an assurance of the quality and consistency of the finished product. Acceptance limits have been justified with respect to conventional pharmaceutical requirements and, where appropriate, safety. Test methods have been described and adequately validated, as appropriate. Batch data are provided for three commercial-scale batches of the product, which demonstrate that the batches are compliant with the proposed release specifications. Certificates of Analysis have been provided for any reference standards used.

**Container Closure System**

The finished product is licensed for marketing in a Type I clear glass ampoules of 2ml (10mg/2ml) and 5ml (15mg/3ml). Each ml of solution for injection or infusion contains 5mg of midazolam. Ampoules are packed in units of 10. The MAH has stated that not all pack sizes may be marketed and has committed to submitting mock-ups for all packaging for assessment before those pack sizes are commercially marketed. All primary product packaging complies with Directive 2002/72/EC (as amended), concerning products in contact with parenteral products.

**Stability**

Finished product stability studies have been conducted in accordance with current guidelines and results were within the proposed specification limits. Based on the results, a shelf-life of
2 years has been set, when the ampoule is unopened, which is satisfactory. This medicinal product does not require any special temperature storage conditions. Keep the ampoules in the outer carton in order to protect from light.

Finished product stability studies have been carried out after reconstitution as well as after dilution in an appropriate diluent. For storage conditions in both cases see Section 6.3 of the Summary Product Characteristics (SmPC).

Compatibility Studies
The stability of Midazolam 5mg/ml Solution for injection or infusion was studied when diluted in the following infusion fluids:
- Dextrose 4% with sodium chloride 0.18%
- Dextrose/Glucose 5% or Sodium chloride 0.9%

The stability of these solutions was monitored by determining the physiochemical parameters such as appearance of solution, pH, assay, and related substances.

Dilution with the infusion fluids listed above with ampoules of Midazolam 5mg/ml Solution for injection or infusion, maintained all the physical and chemical characteristics within specification, after 24 hours of storage at 2-8°C/ambient relative humidity.

Bioequivalence Study
The product is formulated for administration as a solution by the intravenous route. Hence there is no requirement for a bioequivalence study.

Quality Overall Summary
A satisfactory quality overview is provided and has been prepared by an appropriately qualified expert. The curriculum vitae of the expert has been provided.

Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL), Labels
The SmPC, PIL and labelling are pharmaceutically acceptable. Colour mock-ups of the labelling and PIL have been provided. The labelling is satisfactory and fulfils the statutory requirements for Braille.

The applicant has submitted results of a bridging report has been submitted that refers to the parent PILs for Midazolam Injection BP 2mg/ml in a prefilled syringe PL 12064/0101 (marketed by Aurum Pharma Ltd) and Methylthioninium Chloride Injection USP 1% PL 00156/0039 (marketed by Martindale Pharmaceuticals Ltd). The results indicate that the PIL is well-structured and organised, easy to understand and written in a comprehensive manner. The test shows that the patients/users are able to act upon the information that is contains.

MAA Form
The MAA form is pharmaceutically satisfactory.

Conclusion
The test product is pharmaceutically equivalent to the reference product, which has been licensed in the UK for over 10 years. Given the route of administration and pharmaceutical form, it is not necessary to perform a bioequivalence study.

There are no objections to approval of Midazolam 5mg/ml Solution for injection or infusion from a pharmaceutical point of view.
III.2 PRE-CLINICAL ASPECTS
The pharmacodynamic, pharmacokinetic and toxicological properties of midazolam hydrochloride are well-known. Therefore, no further studies are required and the applicant has provided none.

The pre-clinical overview was written by a suitably qualified person and is satisfactory. The *curriculum vitae* of the expert has been provided.

The SmPC is satisfactory from a pre-clinical viewpoint and is consistent with that for the reference product.

There are no objections to approval of Midazolam 5mg/ml Solution for injection or infusion from a pre-clinical point of view.

III.3 CLINICAL ASPECTS
*Pharmacokinetics*
No new data have been submitted and none are required for an application of this type.

Midazolam 5mg/ml Solution for injection or infusion is a generic version of Hypnovel 10mg/2ml solution for injection. The use of the reference product is well-established in the UK. Both products contain the same quantitative and qualitative composition of the active ingredient, midazolam.

According to CPMP guidelines, the applicant is not required to submit a bioequivalence study if the product is to be administered as an aqueous intravenous solution containing the same active substance, in the same concentration as the currently authorised product (CPMP/EWP/QWP/1401/98 rev.1/Corr**- Annex II- Parenteral solutions).

*Pharmacodynamics*
No new data have been submitted and none are required for an application of this type.

*Clinical efficacy*
No new data have been submitted and none are required for an application of this type.

*Clinical safety*
No new safety data have been submitted or required for this generic application. As midazolam is a well-known product with an acceptable adverse event profile, this is satisfactory.

*Expert Report*
A satisfactory clinical overview is provided, and has been prepared by an appropriately qualified physician. The *curriculum vitae* of the expert has been provided.

*Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL), Labels*
The SmPC and PIL are medically acceptable, and consistent with those for the reference product. The labelling is medically acceptable and in-line with current requirements.

*MAA form*
The MAA form is medically satisfactory.
Conclusion
There are no objections to approval of Midazolam 5mg/ml Solution for injection or infusion from a clinical point of view.
IV OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT

QUALITY
The important quality characteristics of Midazolam 5mg/ml Solution for injection or infusion are well-defined and controlled. The specifications and batch analytical results indicate consistency from batch to batch. There are no outstanding quality issues that would have a negative impact on the benefit/risk balance.

PRE-CLINICAL
No new pre-clinical data were submitted and none are required for an application of this type.

EFFICACY
The applicant’s Midazolam 5mg/ml Solution for injection or infusion has been demonstrated to be a generic version of the reference product Hypnovel 10mg/2ml solution for injection (PL 00031/0126) licensed to Roche Products Limited.

No new or unexpected safety concerns arise from this application.

PRODUCT LITERATURE
The SmPC and PIL are acceptable, and consistent with those for the reference product. The labelling is acceptable and in-line with current requirements.

To satisfy the requirements of Article 59(3) of Directive 2001/83/EC (as amended), a bridging report has been submitted that refers to the parent PILs for Midazolam Injection BP 2mg/ml in a prefilled syringe PL 12064/0101 (marketed by Aurum Pharma Ltd) and Methylthioninium Chloride Injection USP 1% PL 00156/0039 (marketed by Martindale Pharmaceuticals Ltd). The results show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

BENEFIT/RISK ASSESSMENT
The quality of the product is acceptable, and no new preclinical or clinical safety concerns have been identified. The qualitative and quantitative assessment supports the claim that the applicant’s Midazolam 5mg/ml Solution for injection or infusion and the reference product Hypnovel 10mg/2ml solution for injection (PL 00031/0126) licensed to Roche Products Limited are interchangeable. Extensive clinical experience with midazolam hydrochloride is considered to have demonstrated the therapeutic value of the active substance. The benefit/risk is, therefore, considered to be positive.
Module 6

STEPS TAKEN AFTER INITIAL PROCEDURE - SUMMARY

<table>
<thead>
<tr>
<th>Date submitted</th>
<th>Application type</th>
<th>Scope</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>